5 Simple Statements About ABBV-744 clinical trial phase 1 results Explained
In Section C, participants will get ABBV-744 and oral navitoclax. In Phase D, members will receive ABBV-744 and ruxolitinib. Individuals will get treatment until sickness progression or even the contributors are unable to tolerate the study drugs.Ubiquitin-linked proteins that control the stability of essential super enhancer-mediated proteins have